根治性放化疗治疗鼻腔鼻窦未分化癌。

Definitive-intent (chemo)radiotherapy for sinonasal undifferentiated carcinoma.

机构信息

Department of Radiation Oncology, Ear, Nose & Throat Hospital of Fudan University, 83 Fenyang Road, Shanghai, China.

出版信息

Br J Radiol. 2023 Jan 1;96(1141):20220244. doi: 10.1259/bjr.20220244. Epub 2022 Nov 28.

DOI:10.1259/bjr.20220244

PMID:36317997

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10997022/

Abstract

OBJECTIVE

The current study aimed to investigate the value of definitive-intent (chemo)radiotherapy in treating sinonasal undifferentiated carcinoma (SNUC) in a single institution.

METHODS

The medical records of 21 patients with SNUC treated with definitive-intent (chemo)radiotherapy between 2011 and 2021 in one single institution were retrospectively reviewed. We analyzed the treatment efficiency and long-term survivals.

RESULTS

A total of 21 patients were included in this cohort, 12 patients presented with T4 stage at diagnosis, and 6 in T1/T2, 3 in T3 stage. Nine patients (42.9%, 9/21) showed cervical lymph node metastases. All the patients were scheduled to receive definitive (chemo)radiotherapy and five patients had been performed surgery for residual tumor after (chemo)radiotherapy. 66.7% (14/21) of patients had a complete response after the completion of treatment, 23.8% (5/21) of partial response, one of stable disease, and one of progressed disease. The 3-year overall survival of the entire group were 86.2%, and the 3-year progress-free survival were 66.3%, respectively. 52.4% of the patients (11/21) presented orbit invasion, compared with patients without orbit invasion, the patients who had orbit invasion were not found to have significantly poor 3-year overall survival (87.5% 83.3%, = 0.38) and 3-year progression-free survival (75.0% 55.3%, = 0.59).

CONCLUSION

Definitive-intent (chemo)radiotherapy could be the preferred treatment for patients with advanced SNUC, and salvage surgery should be performed for the lesions showing stable disease, progressed disease, or residual tumor.

ADVANCES IN KNOWLEDGE

The value of definitive chemoradiotherapy in treating sinonasal undifferentiated carcinoma.

摘要

目的

本研究旨在探讨单中心采用明确意向（放化疗）治疗鼻腔鼻窦未分化癌（SNUC）的价值。

方法

回顾性分析 2011 年至 2021 年期间在单中心接受明确意向（放化疗）治疗的 21 例 SNUC 患者的病历资料。分析治疗效果和长期生存情况。

结果

共纳入 21 例患者，12 例初诊时为 T4 期，6 例为 T1/T2 期，3 例为 T3 期，9 例（42.9%，9/21）出现颈部淋巴结转移。所有患者均接受明确（放化疗）治疗，5 例患者在（放化疗）后行残余肿瘤切除术。治疗完成后，66.7%（14/21）的患者完全缓解，23.8%（5/21）的患者部分缓解，1 例稳定，1 例进展。全组患者 3 年总生存率为 86.2%，无进展生存率为 66.3%。52.4%（11/21）的患者存在眼眶侵犯，与无眼眶侵犯的患者相比，眼眶侵犯的患者 3 年总生存率（87.5%比 83.3%， = 0.38）和 3 年无进展生存率（75.0%比 55.3%， = 0.59）差异无统计学意义。